We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
News

Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders

Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
News

Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

“We expect the synergy resulting from this partnership will result in novel breakthrough therapies that will ultimately benefit patients afflicted with life threatening diseases.”

"We are very pleased to enter into this collaboration with Chemizon whose experienced management team has a track record of success in creating promising drug candidates," said Dr. Jin Li, President of Shenogen Pharma Group. "This collaboration underscores our commitment towards creating orally administered, small molecule modulators of the non-classical Estrogen Receptor pathway that target indications including metastatic breast cancer and osteoporosis.”

Chemizon will be responsible for a spectrum of activities for an integrated drug development program including lead optimization, assay development, ADME, DMPK, Computational chemistry, and animal pharmacology. Financial details of the transaction were not disclosed.

"We are delighted that Shenogen, a world leader in the field of non-classical estrogen receptor signaling, chose Chemizon as their partner," said Dr. Anthony D. Piscopio, Chief Executive Officer, of Chemizon. "We expect the synergy resulting from this partnership will result in novel breakthrough therapies that will ultimately benefit patients afflicted with life threatening diseases.”
Advertisement